Skip to main content

Table 1 Relationships between CXCR4, CXCL12, and Cyclin D1 expression levels and clinicopathologic characteristics of sporadic MPNST patients

From: The prognostic value of C-X-C motif chemokine receptor 4 in patients with sporadic malignant peripheral nerve sheath tumors

Clinical characteristic

Total (cases)

CXCR4 expression [cases (%)]

CXCL12 expression [cases (%)]

Cyclin D1 expression [cases (%)]

High

Low

χ2

P

High

Low

χ2

P

High

Low

χ2

P

Sex

   

0.420

0.517

  

1.008

0.315

  

2.259

0.133

 Male

31

9 (29.0)

22 (71.0)

  

19 (61.3)

12 (39.7)

  

6 (19.4)

25 (80.6)

  

 Female

27

10 (37.0)

17 (63.0)

 

13 (48.1)

14 (51.9)

 

10 (37.0)

17 (63.0)

 

Age (years)

   

0.105

0.745

  

1.277

0.258

  

0.840

0.359

 ≥ 40

38

13 (34.2)

25 (65.8)

  

23 (60.5)

15 (39.5)

  

9 (23.7)

29 (76.3)

  

 < 40

20

6 (30.0)

14 (70.0)

 

9 (45.0)

11 (55.0)

 

7 (35.0)

13 (65.0)

 

Tumor site

   

2.105

0.349

  

0.512

0.774

  

1.045

0.593

 Head/neck

10

3 (30.0)

7 (70.0)

  

5 (50.0)

5 (50.0)

  

2 (20.0)

8 (80.0)

  

 Trunk

23

10 (43.5)

13 (56.5)

 

14 (60.9)

9 (39.1)

 

8 (37.8)

15 (62.2)

 

 Extremity

25

6 (24.0)

19 (76.0)

 

13 (52.0)

12 (48.0)

 

6 (24.0)

19 (76.0)

 

Tumor size (cm)a

   

< 0.001

1.000

  

1.612

0.447

  

0.397

0.820

 < 5

21

7 (30.0)

14 (70.0)

  

14 (70.0)

7 (30.0)

  

5 (23.8)

16 (76.2)

  

 5–10

21

7 (30.0)

14 (70.0)

 

11 (52.4)

10 (47.6)

 

6 (28.6)

15 (71.4)

 

 > 10

15

5 (33.3)

10 (66.7)

 

7 (46.7)

8 (53.3)

 

5 (33.3)

10 (66.7)

 

AJCC stageb

   

2.400

0.494

  

1.679

0.642

  

2.484

0.478

 I

6

1 (16.7)

5 (83.3)

  

3 (50.0)

3 (50.0)

  

2 (33.3)

4 (66.7)

  

 II

32

13 (40.6)

19 (59.4)

 

20 (62.5)

12 (37.5)

 

9 (28.1)

23 (71.9)

 

 III

7

2 (28.6)

5 (71.4)

 

4 (57.1)

3 (42.9)

 

3 (42.9)

4 (57.1)

 

 IV

10

2 (20.0)

8 (80.0)

 

4 (40.0)

6 (60.0)

 

1 (10.0)

9 (90.0)

 

Radiotherapyc

   

0.196

0.658

  

0.252

0.615

  

0.163

0.686

 Yes

21

6 (28.6)

15 (71.4)

  

11 (52.4)

10 (47.6)

  

7 (33.3)

14 (66.7)

  

 No

32

11 (34.3)

21 (65.7)

 

19 (59.4)

13 (40.6)

 

9 (28.1)

23 (71.9)

 

Chemotherapyd

   

0.994

0.319

  

0.065

0.799

  

0.152

0.697

 Yes

22

5 (22.7)

17 (77.3)

  

12 (54.5)

10 (45.5)

  

6 (27.3)

16 (72.7)

  

 No

31

11 (35.5)

20 (64.5)

 

18 (58.1)

13 (41.9)

 

10 (32.3)

21 (67.7)

 

Surgery type

   

1.069

0.301

  

4.416

0.036

  

1.569

0.210

 Wide resection

36

10 (27.8)

26 (72.2)

  

16 (44.4)

20 (55.6)

  

12 (33.3)

24 (66.7)

  

 Marginal resection

22

9 (40.9)

13 (59.1)

 

16 (72.7)

6 (27.3)

 

4 (18.2)

18 (81.8)

 

Recurrence

   

1.046

0.306

  

1.384

0.239

  

0.429

0.513

 Yes

33

9 (27.3)

24 (72.7)

  

16 (48.5)

17 (51.5)

  

8 (24.2)

25 (75.8)

  

 No

25

10 (40.0)

15 (60.0)

 

16 (64.0)

9 (36.0)

 

8 (32.0)

17 (68.0)

 

Metastasis

   

0.834

0.361

  

1.277

0.258

  

0.840

0.359

 Yes

20

5 (25.0)

15 (75.0)

  

9 (45.00)

11 (55.0)

  

7 (35.0)

13 (75.0)

  

 No

38

14 (36.8)

24 (63.2)

 

23 (60.5)

15 (39.5)

 

9 (23.7)

29 (76.3)

 
  1. MPNST malignant peripheral nerve sheath tumor, CXCR4 C-X-C motif chemokine receptor 4, CXCL12 C-X-C motif chemokine ligand 12, AJCC American Joint Committee on Cancer
  2. aTumor size information is missing for 1 patient
  3. bAJCC stage information is missing for 3 patients
  4. cRadiotherapy information is missing for 5 patients
  5. dChemotherapy information is missing for 5 patients
Back to article page

Cancer Communications

ISSN: 2523-3548

Contact us